Release of cysteinyl leukotrienes with aspirin stimulation and the effect of prostaglandin E2 on this release from peripheral blood leucocytes in aspirin-induced asthmatic patients

Clinical and Experimental Allergy

Volumn 31, Issue 10, 2001, Pages 1615-1622

  Celik G ^a,c   Bavbek, S ^a   Misirligil, Z ^a   Melli, M ^a,b  

^a Division of Allergic Diseases   (Turkey)

^b ANKARA UNIVERSITY   (Turkey)

^c NONE   (Turkey)

Author keywords

Aspirin induced asthma; Cysteinyl leukotrienes; Prostaglandin E2

Indexed keywords

ACETYLSALICYLIC ACID; PEPTIDOLEUKOTRIENE; PROSTAGLANDIN E2;

ADULT; ARTICLE; ASTHMA; BLOOD; CELL LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG INDUCED DISEASE; ENZYME IMMUNOASSAY; FEMALE; HUMAN; IN VITRO STUDY; LEUKOCYTE; MALE; PRIORITY JOURNAL;

ADULT; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; ASTHMA; CYSTEINE; CYTOCHALASIN B; DINOPROSTONE; FEMALE; HUMANS; LEUKOCYTES; LEUKOTRIENES; MALE; N-FORMYLMETHIONINE LEUCYL-PHENYLALANINE; STIMULATION, CHEMICAL;

EID: 0034786727     PISSN: 09547894     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2222.2001.01074.x     Document Type: Article

References (39)

1. Intolerance to aspirin. Clinical studies and consideration of its pathogenesis
2. Aspirin-sensitive rhinosinusitis/asthma syndrome -Pathophysiology and management
3. Mechanism of aspirin-induced asthma
4. Mechanism of bronchospasm in aspirin-sensitive asthma
5. Aspirin-induced asthma: Advances in pathogenesis and management
6. The role of leukotrienes in asthma and allergic rhinitis
7. The leukotrienes: Mediators of chronic inflammation in asthma
8. Biosynthesis of cysteinyl leukotrienes in aspirin-intolerant asthma
9. Benefits from adding the 5-lipoxygenase inhibitor Zileuton to conventional therapy in aspirin-intolerant asthmatics
10. Leukotriene antagonists and synthesis inhibitors: New directions in asthma therapy
11. The role of leukotriene modifiers in the treatment of asthma
12. Cysteinyl leukotrienes overproduction and mast cell activation in aspirin-provoked bronchospasm in asthma
13. 4 excretion in aspirin-sensitive asthma
14. 4 in bronchial asthma
15. 4 during aspirin-induced asthma
16. 4 and histamine in asthmatics
17. 2 in patients with aspirin-sensitive asthma
18. Release of leukotrienes, prostaglandins, and histamine into nasal secretions of aspirin-sensitive asthmatics during reaction to aspirin
19. Release of peptide leukotriene into nasal secretions after local instillation of aspirin in aspirin-sensitive asthmatic patients
20. Bronchial aspirin challenge causes specific eicosanoid response in aspirin-sensitive asthmatics
21. Increased in vitro cysteinyl leukotriene release from blood leukocytes in patients with asthma, nasal polyps, and aspirin intolerance
22. 4 levels in asymptomatic bronchial asthma
23. Eicosanoid mediator expression in mononuclear and poly-morphonuclear cells in normal subjects and patients with atopic asthma and cystic fibrosis
24. Means of increasing sensitivity of an in vitro diagnostic test for aspirin intolerance
25. Prostanoid biosynthesis and mechanism of action
26. 2
27. 2 mechanism
28. 2
29. Dispersed human mast cells. Pharmacologic aspects and comparison with human lung fragments
30. E2 on airway conductance in healthy subjects and asthmatic patients
31. 2 on allergen-induced asthma
32. 2 on exercise-induced broncho-constriction in asthmatic subjects
33. Aspects of bronchial reactivity to prostaglandins and aspirin in asthmatic patients
34. 2 on bronchial reactivity to sodium metabi-sulphite and methacholine in patients with asthma
35. 2 on airway obstruction induced by aspirin in aspirin-intolerant asthmatics
36. 1) on aspirin-induced bronchoconstriction in aspirin sensitive asthma
37. Dynamics of eicosanoids in peripheral blood cells during bronchial provocation in aspirin-intolerant asthmatics
38. Arachidonic acid metabolism in nasal tissue and peripheral blood cells in aspirin intolerant asthmatics
39. [3H]acetylcholine release from isolated human bronchi